688075 安旭生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入403,26827.56%503,3576,165,8841,589,2791,199,766
减:营业总成本390,13680.82%442,7091,967,504712,620429,537
    其中:营业成本233,45347.26%290,4451,554,904549,181289,012
               财务费用6,623-107.27%(70,937)(533,589)23,08533,398
               资产减值损失(1,317)-150.66%(23,966)(763,897)(11,170)(2,510)
公允价值变动收益25,394-181.50%(54,802)(9,421)102--
投资收益87,579-25.50%140,10758,41811,8401,261
    其中:对联营企业和合营企业的投资收益------------
营业利润144,006-31.79%167,4843,528,837865,073761,824
利润总额144,007-30.30%143,8173,519,508864,620761,442
减:所得税费用8,258-59.20%2,852475,336126,094112,450
净利润135,748-27.16%140,9653,044,172738,526648,992
减:非控股权益(35)-92.57%(589)(502)----
股东净利润135,784-27.33%141,5543,044,673738,526648,992

市场价值指针
每股收益 (元) *1.070-27.21%1.11023.95010.55014.110
每股派息 (元) *0.400--0.4005.0003.880--
每股净资产 (元) *40.534-0.09%40.20659.73042.49717.650
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容